Hemostatic Disorders in Type 1 Diabetes Mellitus

被引：34

作者：

Targher, Giovanni ^{[1
]}

Chonchol, Michel ^{[2
]}

Zoppini, Giacomo ^{[1
]}

Franchini, Massimo ^{[3
]}

机构：

[1] Univ Verona, Dept Med, Endocrinol Sect, I-37126 Verona, Italy

[2] Univ Colorado, Denver Hlth Sci Ctr, Div Renal Dis & Hypertens, Aurora, CO USA

[3] Univ Hosp Parma, Immunohematol & Transfus Ctr, Dept Pathol & Lab Med, Parma, Italy

来源：

SEMINARS IN THROMBOSIS AND HEMOSTASIS | 2011年 / 37卷 / 01期

关键词：

Type; 1; diabetes; coagulation; fibrinolysis; hemostatic disorders; ACTIVATABLE FIBRINOLYSIS INHIBITOR; SOLUBLE CD40 LIGAND; ENDOTHELIAL DYSFUNCTION; MICROVASCULAR COMPLICATIONS; ADHESION MOLECULES; MARKERS; INFLAMMATION; ASSOCIATION; NEPHROPATHY; COAGULATION;

D O I：

10.1055/s-0030-1270072

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This review summarizes current knowledge of the adverse effects of type 1 diabetes mellitus on coagulation and fibrinolysis. Although further larger studies are needed to provide more definitive information, patients with type 1 diabetes exhibit a proinflammatory/procoagulant condition deriving from increased platelet adhesiveness, activation of the coagulation system, and decreased plasma fibrinolytic potential. This review also focuses on recent data from large prospective studies suggesting a strong association between procoagulant imbalance and development of chronic vascular complications in people with type 1 diabetes. It is likely that a greater appreciation of the intimate interactions between endothelial integrity, coagulation and fibrinolytic factors, and platelets in type 1 diabetes will provide a greater understanding of the risk of developing cardiovascular disease and microvascular complications such as nephropathy and retinopathy in this patient population.

引用

页码：58 / 65

页数：8

共 44 条

[1] Amer Diabet Assoc, 2011, DIABETES CARE, V34, pS11, DOI [10.2337/dc10-S062, 10.2337/dc14-S081, 10.2337/dc11-S011, 10.2337/dc13-S011, 10.2337/dc13-S067, 10.2337/dc12-s064, 10.2337/dc11-S062, 10.2337/dc10-S011, 10.2337/dc12-s011]
[2] Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications
Antovic, JP
Yngen, M
Östenson, CG
Antovic, A
Wallen, HN
Jorneskög, G
Blombäck, M
[J]. BLOOD COAGULATION & FIBRINOLYSIS, 2003, 14 (06) : 551 - 556
[3] Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years - Association with mortality and decline of glomerular filtration rate
Astrup, Anne Sofie
Tarnow, Lise
Pietraszek, Lotte
Schalkwijk, Casper G.
Stehouwer, Coen D. A.
Parving, Hans-Henrik
Rossing, Peter
[J]. DIABETES CARE, 2008, 31 (06) : 1170 - 1176
[4] Blann AD, 1998, DIABETIC MED, V15, P634, DOI 10.1002/(SICI)1096-9136(199808)15:8<634::AID-DIA636>3.3.CO
[5] 2-#
[6] The pathobiology of diabetic complications - A unifying mechanism
Brownlee, M
[J]. DIABETES, 2005, 54 (06) : 1615 - 1625
[7] COAGULATION AND FIBRINOLYTIC SYSTEM IMPAIRMENT IN INSULIN-DEPENDENT DIABETES-MELLITUS
CARMASSI, F
MORALE, M
PUCCETTI, R
DENEGRI, F
MONZANI, F
NAVALESI, R
MARIANI, G
[J]. THROMBOSIS RESEARCH, 1992, 67 (06) : 643 - 654
[8] Markers of endothelial dysfunction in the prediction of coronary artery disease in type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications study
Costacou, T
Lopes-Virella, MF
Zgibor, JC
Virella, G
Otvos, J
Walsh, M
Orchard, TJ
[J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2005, 19 (04) : 183 - 193
[9] Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus -: Role of interleukin-6 and disease duration
Davì, G
Chiarelli, F
Santilli, F
Pomilio, M
Vigneri, S
Falco, A
Basili, S
Ciabattoni, G
Patrono, C
[J]. CIRCULATION, 2003, 107 (25) : 3199 - 3203
[10] Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes
Devaraj, S
Glaser, N
Griffen, S
Wang-Polagruto, J
Miguelino, E
Jialal, I
[J]. DIABETES, 2006, 55 (03) : 774 - 779

← 1 2 3 4 5 →